[1]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312-316.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
　Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):312-316.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
点击复制

11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第4期
页码:
312-316
栏目:
临床研究
出版日期:
2018-07-25

文章信息/Info

Title:
Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation
作者:
麻广宇;  刘家金;  徐白萱;  陈英茂;  张晓军;  刘健;  张锦明
100853 北京, 中国人民解放军总医院核医学科
Author(s):
Ma Guangyu;  Liu Jiajin;  Xu Baixuan;  Chen Yingmao;  Zhang Xiaojun;  Liu Jian;  Zhang Jinming
Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China
关键词:
癌; 肝细胞; 氟脱氧葡萄糖F18; 乙酸盐类; 正电子发射断层显像计算机体层摄影术
Keywords:
Carcinoma; hepatocellular; Fluorodeoxyglucose F18; Acetates; Positron emission tomography computed tomography
DOI:
10.3760/cma.j.issn.1673-4114.2018.04.004
摘要:
目的 探讨11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌（HCC）复发与转移监测中的应用价值。方法 回顾性分析2015年1月至2016年12月行11C-乙酸盐和18F-FDG PET/CT躯干显像的10例中、高分化HCC男性患者，其中，中分化HCC 6例，高分化HCC 4例。患者经手术或介入治疗后，甲胎蛋白进行性升高，比较11C-乙酸盐和18F-FDG PET/CT的诊断价值。PET图像上代谢高于正常肝脏组织的病灶判定为阳性，低于或类似于正常肝脏组织的病灶判定为阴性。通过勾画感兴趣区计算病灶及本底最大标准化摄取值（SUVmax）及靶/本底比值（T/B）。所有患者最终通过病理或影像学检查确诊转移或复发。结果 11C-乙酸盐显像发现18个阳性病灶，灵敏度为100%（18/18）；18F-FDG显像发现5个阳性病灶，灵敏度为27.8%（5/18）；两种示踪剂同时发现5个阳性病灶（在4例中分化HCC患者中），11C-乙酸盐显像探测病灶的灵敏度与两种示踪剂联合显像相同。11C-乙酸盐显像病灶SUVmax为1.3~14.2，T/B为1.1~14.3；18F-FDG显像病灶SUVmax为0.5~3.4，T/B为0.6~1.1。8例患者（13个病灶）病理证实为肿瘤复发或转移，2例患者（5个病灶）3个月后复查PET/CT或CT证实为转移。结论 11C-乙酸盐显像可显著提高中、高分化HCC复发与转移诊断的灵敏度；推荐使用11C-乙酸盐显像用于监测中、高分化HCC的复发与转移。
Abstract:
Objectives To investigate the value of 11C-acetate PET/CT imaging in the detection of the recurrence and metastasis of hepatocellular carcinoma (HCC) with high or medium differentiation. Methods A total of 10 patients who underwent surgical or interventional therapy, had moderately or highly differentiated HCC, underwent 11C-acetate and 18F-FDG PET/CT trunk imaging from January 2015 to December 2016 were retrospectively analyzed. Progressive increases in alpha fetoprotein were observed in the patients after the treatment. 11C-acetate and 18F-FDG PET/CT scan were performed on the patients in one week, and the diagnostic values of the two tracers were compared. In the PET images, the lesion was positive when the metabolic level of the lesion was higher than that of a normal liver tissue and negative when the metabolic level of the lesion was lower than or same as that of a normal liver tissue. The maximum standardized uptake value(SUVmax) and the ratio of target to background(T/B) were calculated by outlining the areas of interest. All patients were diagnosed with metastasis or recurrence by pathology or imaging examination. Results Six patients had moderately differentiated HCC and four patients had highly differentiated HCC. 11C-acetate imaging revealed 18 positive lesions, and the sensitivity was 100%(18/18). Five positive lesions were found in 18F-FDG images, and the sensitivity was 27.8%(5/18). Two tracers revealed five positive lesions (in four patients with moderately differentiated HCC). The sensitivity of 11C-acetate imaging to detect lesions was the same as that of double tracers combined imaging. The SUVmax range of 11C-acetate imaging was 1.3-14.2, and the range of T/B was 1.1-14.3. The SUVmax range of 18F-FDG imaging was 0.5-3.4, and the range of T/B was 0.6-1.1. Eight patients (13 lesions) were pathologically confirmed to have tumor recurrence or metastasis, and two patients (5 lesions) proved to be metastatic after 3 months of follow-up. Conclusions 11C-acetate imaging can significantly improve the sensitivity of the diagnosis of recurrence and metastasis of moderately and highly differentiated HCC. 11C-acetate imaging is expected to replace 18F-FDG imaging in monitoring recurrence and metastasis in moderately and highly differentiated HCC.

参考文献/References:

[1] Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses[J]. J Nucl Med, 2003, 44(2):213-221.
[2] Larsson P, Arvidsson D, Björnstedt M, et al. Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma[J]. Mol Imaging Radionucl Ther, 2012, 21(1):6-12. DOI:10.4274/Mirt.87.
[3] Cheung TT, Ho CL, Lo CM, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria:surgeon’s perspective[J]. J Nucl Med, 2013, 54(2):192-200. DOI:10.2967/jnumed.112.107516.
[4] Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12):1912-1921. DOI:10.2967/jnumed.108.055087.
[5] Huo L, Dang Y, Lv J, et al. Application of dual phase imaging of 11C-acetate positron emission tomography on differential diagnosis of small hepatic lesions[J/OL]. PLoS One, 2014, 9(5):e96517[2018-01-12]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015995. DOI:10.1371/journal.pone.0096517.
[6] Magini G, Farsad M, Frigerio M, et al. C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma[J]. Clin Nucl Med, 2009, 34(10):659-665. DOI:10.1097/RLU.0b013e3181b53488.
[7] Ho CL, Chen S, Cheng TK, et al. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma[J]. Radiology, 2011, 258(2):515-523. DOI:10.1148/radiol.10100672.
[8] Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma[J]. J Nucl Med,2007, 48(6):902-909. DOI:10.2967/jnumed.106.036673.
[9] Yoon KT, Kim JK, Kim DY, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma[J]. Oncology, 2007, 72 Suppl 1:S104-110. DOI:10.1159/000111715.
[10] Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation:acetate metabolism in tumor cells[J]. Nucl Med Biol, 2001, 28(2):117-122.
[11] Salem N, Kuang Y, Corn D, et al.[(Methyl)1-11C]-acetate metabolism in hepatocellular carcinoma[J]. Mol Imaging Biol, 2011, 13(1):140-151. DOI:10.1007/s11307-010-0308-y.
[12] Polanec SH, Andrzejewski P, Baltzer PAT, et al. Multiparametric[11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer[J/OL]. PLoS One, 2017, 12(7):e0180790[2018-01-12]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515396. DOI:10.1371/journal.pone.0180790.
[13] Ho CL, Chen S, Ho KM, et al. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma[J]. Clin Nucl Med, 2012, 37(11):1075-1082. DOI:10.1097/RLU.0b013e318266-cde2.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
　Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[3]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[4]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
　Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[5]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[6]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
　LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[7]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
　YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[8]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
　LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[9]朱晓琳,李强.肝腺瘤的影像诊断现状及进展[J].国际放射医学核医学杂志,2011,35(2):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
　ZHU Xiao-lin,LI Qiang.Status and advances in imaging diagnsis of hepatic adenoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
[10]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
　LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[11]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
　Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[12]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
　Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[13]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
　ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[14]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
　LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[15]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
　ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):23.
[16]周云,刘璐,宋进华.经肝动脉灌注90Y微球治疗肝癌的研究进展[J].国际放射医学核医学杂志,2006,30(6):321.
　ZHOU Yun,LIU Lu,SONG Jin-hua.Clinical researched progress of intra-arterial radioembolization with 90Y-glass microspheres for treatment of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):321.
[17]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
　Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
[18]陈佩和,徐文贵,李小凤,等.肝细胞肝癌的葡萄糖代谢机制及在PET显像中的应用价值[J].国际放射医学核医学杂志,2018,(6):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]
　Chen Peihe,Xu Wengui,Li Xiaofeng,et al.Glycometabolism mechanism in hepatocellular carcinoma and its application in PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]

备注/Memo

备注/Memo:
收稿日期:2018-01-12。
基金项目:国家自然科学基金（81371593）
通讯作者:张锦明,Email:zhangjm301@163.com
更新日期/Last Update: 2018-07-25